Thor Medical Stock Börse Stuttgart

8NN

NO0010597883

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 22:54:41 09/07/2026 +03			5-day change	1st Jan Change
0.3870 ^EUR	+1.44%		+3.11%	-10.02%

06-16	Thor Medical ASA Announces Retirement of Alf Bjørseth from EVP Business Development, Effective June 30, 2026	CI
05-29	Thor Medical ASA Enters Collaboration and Supply Agreement With Minerva Imaging	CI

Last Transcript: Thor Medical

Thor Medical ASA, H2 2025 Earnings Call, Feb 26, 2026

02-26

More transcripts

News in other languages: Thor Medical

02/06/22	Actualización de las fuertes variaciones del día: EcoOnline despierta su sector, Klöckner ajuste después de dividendo
02/06/22	Point sur les fortes variations du jour : Saint-Gobain réveille son secteur, Esker trop prudent
19/02/21	Avis d'analystes du jour : L'Oréal, Air France KLM, Nestlé, Orange, Campari, Moncler, BioMérieux, Stratec...
19/02/21	Des PMI et des sorcières pour terminer la semaine
24/11/20	Avis d'analystes du jour : Aston Martin, Idorsia, Innate, Kering, LVMH, Natixis, Richemont, SMCP, Valeo...

More news

Managers and Directors: Thor Medical

Manager	Title	Age	Since
Jasper Kurth CEO	Chief Executive Officer	41	01/08/2024
Brede Høyland Ellingsæter DFI	Director of Finance/CFO	37	01/07/2023
Sindre Hassfjell CTO	Chief Tech/Sci/R&D Officer	-	01/06/2023

Director	Title	Age	Since
Mimi Kristine Berdal BRD	Director/Board Member	67	28/06/2023
John Andersen CHM	Chairman	59	-
Jens Gisle Schnelle BRD	Director/Board Member	-	24/04/2025

More insiders

Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells

Employees

Sector

Biotechnology & Medical Research

Calendar

08-28 - Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
09/07/26	€0.3825	+0.26%
08/07/26	€0.3815	+0.13%
07/07/26	€0.3810	-1.68%
06/07/26	€0.3875	-0.77%
03/07/26	€0.3905	+1.69%

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

4.300NOK

Average target price

3.500NOK

Spread / Average Target

-18.60%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Cap	1.55B 159M 139M 129M 119M 226M 15.21B 229M 1.54B 603M 7.47B 598M 585M 25.87B	P/E 2026 *	-30.7x	P/E 2027 *	-39.1x
Enterprise Value	1.73B 178M 156M 144M 133M 252M 17B 257M 1.72B 675M 8.35B 669M 654M 28.92B	EV / Sales 2026 *	35.4x	EV / Sales 2027 *	10.3x
Free-Float	59.77%	Yield 2026 *	-	Yield 2027 *	-

06-16	Thor Medical ASA Announces Retirement of Alf Bjørseth from EVP Business Development, Effective June 30, 2026	CI
05-29	Thor Medical ASA Enters Collaboration and Supply Agreement With Minerva Imaging	CI
05-29	Thor Medical Lands Deal to Supply Cancer Treatment Isotope	MT
05-29	Thor Medical enters partnership agreement with Minerva Imaging	RE
05-28	Thor Medical, Eckert & Ziegler Close Deal for Lead-212 Supply	MT
05-28	Thor Medical Partners With Eckert & Ziegler	RE
05-28	Eckert & Ziegler SE Enters Partnership with Thor Medical Asa to Enable Access of Lead-212 for the Pharmaceutical Industry	CI
04-17	Thor Medical's New Radiopharmaceuticals Facility Reaches Mechanical Completion	MT
04-17	Thor Medical completes Alphaone production facility at Herøya industrial park	RE
03-27	Thor Medical ASA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Thor Medical Asa Enters into Multiyear Frame Agreement with Node Pharma as for Supply of Radium-224 and Lead-212	CI
03-26	Thor Medical Lands Isotope Supply Deal in Norway	MT
03-26	Thor Medical enters multiyear agreement with Node Pharma	RE

06-12	Thor Medical : TRMED – Executive Management Share Purchase	PU
06-12	Thor Medical : TRMED - Executive Management Share Purchase	PU
05-08	Thor Medical ASA: New share capital registered	PU
05-05	Thor Medical : Issuance of RSU shares and grant of RSUs to members of the board	PU
04-17	Thor Medical ASA: Mechanical Completion Achieved at Herøya Facility, AlphaOne	PU

1 week	+3.11%
Current month	+2.14%
1 month	+3.11%
3 months	-17.07%
6 months	-10.34%
Current year	-10.02%

1 week	0.37	0.4
1 month	0.36	0.4
3 years	0.05	0.51
5 years	0.04	3.03
10 years	0.04	13.39

Thor Medical Stock Börse Stuttgart

Stocks

8NN

NO0010597883

Biotechnology & Medical Research

Valuation: Thor Medical

Chart: Thor Medical

Latest news : Thor Medical

Last Transcript: Thor Medical

Press Releases: Thor Medical

News in other languages: Thor Medical

Quotes and Performance

Course Extremes

Managers and Directors: Thor Medical

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THOR MEDICAL	+1.44%	+3.11%	+91.52%	+209.66%	158M
ARGENX SE	-0.38%	-3.44%	+71.35%	+126.62%	56.71B
WUXI APPTEC CO., LTD.	+4.91%	-3.30%	+71.97%	+92.14%	51.3B
INSMED INCORPORATED	+1.56%	+6.35%	+23.03%	+481.81%	25.26B
BIONTECH SE	-0.66%	-4.61%	-16.76%	-13.39%	23.65B
WUXI BIOLOGICS (CAYMAN) INC.	+3.93%	+7.11%	+44.20%	-1.96%	18.69B
GENMAB A/S	+2.01%	+2.99%	+40.72%	-24.46%	17.71B
PHARMAESSENTIA CORPORATION	-6.84%	+4.81%	+201.88%	+348.11%	17.7B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.92%	+8.90%	+38.48%	-	14.26B
EXELIXIS, INC.	+1.66%	+2.01%	+29.27%	+198.74%	14.1B
Average	+0.60%	+3.45%	+59.57%	+157.48%	26.6B
Weighted average by Cap.	+1.07%	+2.16%	+58.53%	+143.32%

	2026 *	2027 *
Net sales	49M 5.04M 4.41M 4.06M 3.76M 7.14M 481M 7.25M 48.66M 19.07M 236M 18.91M 18.5M 818M	168M 17.27M 15.11M 13.93M 12.89M 24.47M 1.65B 24.87M 167M 65.4M 809M 64.83M 63.43M 2.8B
Net income	-49M -5.04M -4.41M -4.06M -3.76M -7.14M -481M -7.25M -48.66M -19.07M -236M -18.91M -18.5M -818M	-40M -4.11M -3.6M -3.32M -3.07M -5.83M -392M -5.92M -39.72M -15.57M -193M -15.44M -15.1M -668M
Net Debt	183M 18.81M 16.46M 15.17M 14.04M 26.65M 1.8B 27.09M 182M 71.24M 882M 70.62M 69.09M 3.05B	177M 18.19M 15.92M 14.68M 13.58M 25.78M 1.74B 26.21M 176M 68.9M 853M 68.3M 66.82M 2.95B